Dermata Therapeutics (DRMA) Q4 2025 earnings summary

Executive summary

• Announced a strategic pivot in September 2025 from prescription dermatology to direct-to-consumer (DTC) skincare products, launching the Tome brand.

• First DTC product, Foundational Treatment, a once-weekly mask, is set to launch mid-2026, with a Clearing Treatment for acne to follow.

• Hired a new Vice President of Marketing to lead the Tome brand and accelerate DTC strategy.

Financial highlights

• Raised $15.4 million in gross proceeds during 2025 and early 2026, including $4.125 million from a private placement in December 2025.

• Cash and cash equivalents were $7.5 million as of December 31, 2025, up from $3.2 million at the end of 2024.

• Research and development expenses decreased to $2.9 million for 2025 from $8.2 million in 2024, mainly due to the completion of the STAR-1 acne study.

• Selling, general, and administrative expenses increased to $4.8 million in 2025 from $4.3 million in 2024, driven by $0.7 million in marketing expenses.

• Net loss narrowed to $7.6 million in 2025 from $12.3 million in 2024.

Outlook and guidance

• Current cash resources are expected to fund operations into the first quarter of 2027.

• Anticipates launching the Foundational Treatment in mid-2026 and the Clearing Treatment for acne shortly thereafter.